Email Updates

You are here

Striking a Balance in an Antibody Network: A Roadmap for HIV-1 Vaccines

Include in
Published Research

With almost 2 million new HIV-1 infections in 2018, a highly effective vaccine is imperative. Vaccine-elicited HIV-1 antibodies contribute to protection through multiple nonneutralizing activities, but the exact mechanisms remain unknown. In this issue of the JCI, Neidich and associates sought to determine how antibodies contributed to reducing the risk of HIV-1 acquisition in a phase IIb preventative vaccine efficacy trial, HVTN 505.

October 7, 2019
Journal of Clinical Investigation